labcorp holdings inc. - LH
LH
Close Chg Chg %
253.53 -3.84 -1.51%
Closed Market
249.69
-3.84 (1.51%)
Volume: 1.14M
Last Updated:
Jul 11, 2025, 3:59 PM EDT
Company Overview: labcorp holdings inc. - LH
LH Key Data
| Open $252.90 | Day Range 247.67 - 252.90 |
| 52 Week Range 205.95 - 265.72 | Market Cap $21.22B |
| Shares Outstanding 83.67M | Public Float 83.39M |
| Beta 0.82 | Rev. Per Employee N/A |
| P/E Ratio 29.26 | EPS $8.72 |
| Yield 113.55% | Dividend $0.72 |
| EX-DIVIDEND DATE Aug 28, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 731.94K |
LH Performance
| 1 Week | -4.69% | ||
| 1 Month | -4.40% | ||
| 3 Months | 12.72% | ||
| 1 Year | 21.07% | ||
| 5 Years | 70.05% |
LH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
About labcorp holdings inc. - LH
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
LH At a Glance
Labcorp Holdings, Inc.
358 South Main Street
Burlington, North Carolina 27215-5837
| Phone | 1-336-229-1127 | Revenue | 13.01B | |
| Industry | Medical/Nursing Services | Net Income | 746.00M | |
| Sector | Health Services | 2024 Sales Growth | 6.967% | |
| Fiscal Year-end | 12 / 2025 | Employees | 70,000 | |
| View SEC Filings |
LH Valuation
| P/E Current | 29.258 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 25.944 |
| Price to Sales Ratio | 1.488 |
| Price to Book Ratio | 2.375 |
| Price to Cash Flow Ratio | 12.205 |
| Enterprise Value to EBITDA | 12.328 |
| Enterprise Value to Sales | 1.931 |
| Total Debt to Enterprise Value | 0.289 |
LH Efficiency
| Revenue/Employee | 185,841.429 |
| Income Per Employee | 10,657.143 |
| Receivables Turnover | 6.204 |
| Total Asset Turnover | 0.741 |
LH Liquidity
| Current Ratio | 1.443 |
| Quick Ratio | 1.295 |
| Cash Ratio | 0.456 |
LH Profitability
| Gross Margin | 25.89 |
| Operating Margin | 8.748 |
| Pretax Margin | 7.376 |
| Net Margin | 5.735 |
| Return on Assets | 4.25 |
| Return on Equity | 9.368 |
| Return on Total Capital | 4.868 |
| Return on Invested Capital | 5.569 |
LH Capital Structure
| Total Debt to Total Equity | 90.321 |
| Total Debt to Total Capital | 47.457 |
| Total Debt to Total Assets | 39.571 |
| Long-Term Debt to Equity | 75.53 |
| Long-Term Debt to Total Capital | 39.685 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Labcorp Holdings Inc. - LH
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 16.12B | 14.88B | 12.16B | 13.01B | |
Sales Growth
| +15.33% | -7.72% | -18.25% | +6.97% | |
Cost of Goods Sold (COGS) incl D&A
| 10.87B | 10.75B | 9.02B | 9.64B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 940.00M | 828.30M | 580.90M | 899.90M | |
Depreciation
| 570.40M | 569.00M | 361.10M | 643.50M | |
Amortization of Intangibles
| 369.60M | 259.30M | 219.80M | 256.40M | |
COGS Growth
| +16.83% | -1.06% | -16.13% | +6.93% | |
Gross Income
| 5.25B | 4.13B | 3.15B | 3.37B | |
Gross Income Growth
| +12.34% | -21.48% | -23.77% | +7.09% | |
Gross Profit Margin
| +32.60% | +27.73% | +25.86% | +25.89% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.89B | 2.00B | 2.02B | 2.23B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 1.89B | 2.00B | 2.02B | 2.23B | |
SGA Growth
| +10.91% | +5.41% | +1.24% | +10.32% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 101.10M | 355.30M | 398.10M | 51.30M | |
EBIT after Unusual Expense
| 3.26B | 1.77B | 725.60M | 1.09B | |
Non Operating Income/Expense
| 79.20M | (11.00M) | 42.90M | 81.10M | |
Non-Operating Interest Income
| 10.20M | 8.90M | 28.80M | 22.30M | |
Equity in Earnings of Affiliates
| 26.50M | 5.40M | (1.40M) | (1.40M) | |
Interest Expense
| 212.10M | 180.30M | 199.60M | 208.30M | |
Interest Expense Growth
| +2.27% | -14.99% | +10.70% | +4.36% | |
Gross Interest Expense
| 212.10M | 180.30M | 199.60M | 208.30M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 3.13B | 1.58B | 568.90M | 959.50M | |
Pretax Income Growth
| +40.89% | -49.38% | -64.05% | +68.66% | |
Pretax Margin
| +19.39% | +10.64% | +4.68% | +7.38% | |
Income Tax
| 747.10M | 302.00M | 188.50M | 212.40M | |
Income Tax - Current - Domestic
| 717.40M | 229.50M | 222.00M | 172.10M | |
Income Tax - Current - Foreign
| 107.70M | 65.30M | 44.60M | 60.40M | |
Income Tax - Deferred - Domestic
| (78.30M) | 2.40M | (94.70M) | (17.40M) | |
Income Tax - Deferred - Foreign
| 300.00K | 4.80M | 16.60M | (2.70M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 26.50M | 5.40M | (1.40M) | (1.40M) | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 2.38B | 1.28B | 380.40M | 747.10M | |
Minority Interest Expense
| 2.20M | 1.50M | 1.20M | 1.10M | |
Net Income
| 2.38B | 1.28B | 379.20M | 746.00M | |
Net Income Growth
| +52.77% | -46.20% | -70.35% | +96.73% | |
Net Margin Growth
| +14.75% | +8.60% | +3.12% | +5.73% | |
Extraordinaries & Discontinued Operations
| - | - | - | 38.80M | - |
Discontinued Operations
| - | - | - | 38.80M | - |
Net Income After Extraordinaries
| 2.38B | 1.28B | 418.00M | 746.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 2.38B | 1.28B | 418.00M | 746.00M | |
EPS (Basic)
| 24.5843 | 14.0406 | 4.7991 | 8.8915 | |
EPS (Basic) Growth
| +53.72% | -42.89% | -65.82% | +85.27% | |
Basic Shares Outstanding
| 96.70M | 91.10M | 87.10M | 83.90M | |
EPS (Diluted)
| 24.3826 | 13.964 | 4.7717 | 8.8389 | |
EPS (Diluted) Growth
| +53.56% | -42.73% | -65.83% | +85.24% | |
Diluted Shares Outstanding
| 97.50M | 91.60M | 87.60M | 84.40M | |
EBITDA
| 4.30B | 2.96B | 1.70B | 2.04B | |
EBITDA Growth
| +13.33% | -31.23% | -42.36% | +19.55% | |
EBITDA Margin
| +26.68% | +19.88% | +14.02% | +15.67% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 279.294 | |
| Number of Ratings | 23 | Current Quarters Estimate | 4.064 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | 16.075 | |
| Last Quarter’s Earnings | 4.163 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 14.57 | Next Fiscal Year Estimate | 17.609 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 16 | 16 | 18 | 19 |
| Mean Estimate | 4.06 | 3.98 | 16.08 | 17.61 |
| High Estimates | 4.18 | 4.12 | 16.23 | 18.02 |
| Low Estimate | 3.94 | 3.71 | 15.89 | 17.00 |
| Coefficient of Variance | 1.36 | 2.10 | 0.47 | 1.34 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 14 | 15 | 15 |
| OVERWEIGHT | 4 | 4 | 4 |
| HOLD | 5 | 4 | 4 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Labcorp Holdings Inc. - LH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Labcorp Holdings Inc. - LH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 3, 2025 | Kerrii B. Anderson Director | 12,166 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $265 per share | 3,223,990.00 |
| May 6, 2025 | Peter J. Wilkinson SVP, Chief Accounting Officer | 2,054 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $242.26 per share | 497,602.04 |
| May 6, 2025 | Sandra Danett van der Vaart EVP, Chief Legal Officer | 2,244 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $238.36 per share | 534,879.84 |
| Apr 4, 2025 | Megan D. Bailey EVP, Pres, Central Labs & Intl | 2,969 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Megan D. Bailey EVP, Pres, Central Labs & Intl | 3,403 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $232.65 per share | 791,707.95 |
| Apr 4, 2025 | Megan D. Bailey EVP, Pres, Central Labs & Intl | 3,471 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Megan D. Bailey EVP, Pres, Central Labs & Intl | 3,173 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Megan D. Bailey EVP, Pres, Central Labs & Intl | 4,813 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 4, 2025 | Megan D. Bailey EVP, Pres, Central Labs & Intl | 3,267 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $232.65 per share | 760,067.55 |
| Apr 1, 2025 | Brian J. Caveney EVP, Pres of ED, CMO & CSO | 34,176 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 1, 2025 | Mark S. Schroeder EVP, Pres Diagnostics & COO | 4,960 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $231.67 per share | 1,149,083.20 |
| Apr 1, 2025 | Amy B. Summy EVP, Chief Marketing Officer | 6,622 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 1, 2025 | Glenn Andrew Eisenberg Executive Vice President | 37,920 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share | 8,784,926.40 |
| Apr 1, 2025 | Sandra Danett van der Vaart EVP, Chief Legal Officer | 4,144 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share | 960,040.48 |
| Apr 1, 2025 | Peter J. Wilkinson SVP, Chief Accounting Officer | 2,883 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share | 667,904.61 |
| Apr 1, 2025 | Akinbolade Oyegunwa EVP, CIO & CTO | 3,464 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share | 802,504.88 |
| Apr 1, 2025 | Adam H. Schechter President & CEO; Director | 118,651 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 1, 2025 | Mark S. Schroeder EVP, Pres Diagnostics & COO | 9,800 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 1, 2025 | Mark S. Schroeder EVP, Pres Diagnostics & COO | 7,595 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share | 1,759,533.65 |
| Apr 1, 2025 | Amy B. Summy EVP, Chief Marketing Officer | 6,060 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $231.67 per share | 1,403,920.20 |